INTRODUCTION AND OBJECTIVES: Stone extraction devices have become a routine tool after RIRS. Basketing increases the surgical duration and can lead to serious complications such as perforation and avulsion of the ureter wall. Furthermore, obtaining a complete stone fragment removal is still a challenging issue. In this video we present in vitro experiment for a new conception of FlexorÒ Vue Deflecting Endoscopic System (FVDES) use and its in vivo application/ implementation.
The aim of our study is to create and test a new system that is able to routinely, effectively clear the fragments remaining after RIRS.
METHODS: FVDES includes a disposable sheath and a visualization source, originally designed as a flexible endoscope. We placed an irrigator within optical channel so to have the flexor carry out a new function. We created an in vitro study that modelled the lithic fragments remaining post-RIRS. The device was implemented in vivo on 11 consecutive patients treated for primary or recurrent renal stones of medium size (1,5-2,5 cm).
All the procedures were performed using a 200 µm holmium fiber using a flexible ureterorenoscope (Olympus URF-V2) and standard UAS. The FVDES was positioned at the end of procedure in order to improve SFR. The outcomes of interest are feasibility, safety and efficacy. Feasibility was defined as the capacity of positioning and favouring fragment removal according to the Bernulli's principle by the Flexor device. Safety was defined by complication analysis. Efficacy outcomes measured operative time, SFR, hospital stay, re-treatment and rehospitalization. SFR was defined as fragments less than 4 mm assessed by ultrasound and CT. Descriptive statistical analysis was applied.
RESULTS: The experimental in vitro model showed the efficacy of the device, allowing the removal of about 90% of fragments. In vivo, 11 patients (M/F ratio: 7/4, mean age 63.5 AE 8.3) were treated. The stones were located in the lower calyces, and the renal pelvis in 3 and 8 patients, respectively. Medium stone size was 1.8 mm AE 3.2. The procedure with FVDES was feasible in all the patients. Eight patients underwent preoperative ureteral stent. Mean operative time was 82 min AE 13.7 and median hospital stay was of 1.5 day. The SFR after 30 days was 81% (9/11). Post-operatively we had no significant bleeding. 1 patient had fever and required antibiotic treatment for 5 days. No cost/effectiveness study was performed.
CONCLUSIONS: Our in vitro results confirmed the rationale for new conception of FVDES use. In vivo results showed it to be feasible, safe and effective for patients with medium size (1.5 to 2.5 cm) renal stones. The technique we described could allow to avoid the basketing whilst increasing the SFR after RIRS.
The removal of the residual stones could lead to a reduction of the risk of disease reoccurrence and also lower the chances of patients requiring re-treatments. The positive impact may extend to include a reduction in the costs of the procedure. Further studies with larger population are mandatory before the introduction of this technique in our clinical practice.
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MP23-18 A CLINICAL TRACKING PROGRAM FOR URETERAL STENTS INTEGRATED INTO EMR
Fady Ghali*, Dimitri Papagiannopoulos, Roger Sur, Seth Bechis, San Diego, CA INTRODUCTION AND OBJECTIVES: Retained ureteral stents are a common complication with an incidence near 10%. Retained stents can be associated with significant complications and result in both cost and patient morbidity, and often necessitate more involved surgery to remove, largely due to encrustation. As many as 76% of stents are known to encrust after 12 weeks. Many approaches have been proposed to address this issue, including patient wristbands, phone apps, and external registries which have been met with varying limitations and success. These strategies involve increased documentation burden on the surgeon as well as separate electronic systems such as smartphone applications or registries, raising patient privacy concerns. We sought to design and implement an integrated stent tracking system in order to reduce the rate of retained ureteral stents while minimizing added work on the surgeon.
METHODS: We designed and recently implemented a point-ofcare (POC), integrated, stent-tracking program within our hospital EMR (EPIC Hyperspace). At time of surgery, our system generates an alert within EPIC to input the 'expected explant date' of all ureteral stents (implants) placed during the surgery. This information is documented by the circulating nurse at the time that other implant information is entered. The expected explant date is determined by the surgeon and corresponds to the anticipated date of removal. The EPIC system then generates an alert when this expected date has passed, and messages can be sent to the appropriate clinical teams to contact the patient and schedule appropriate followup. We performed a retrospective review of the first 30 patients who underwent stent tracking.
RESULTS: In a pilot study, 30 patients underwent stent placement using the new tracking system, and 26 have had stents successfully removed before the anticipated date of removal. Three patients had stents removed after the expected date, and 1 patient was flagged for missed stent removal and has been subsequently scheduled for a stent removal appointment. We are currently enrolling patients in a database to follow stent removal and assess the efficacy of our tracking
